in the absence of a submission from the holder of the marketing authorisation:
bempedoic acid / ezetimibe (Nustendi®) is not recommended for use within NHSScotland.
Indication under review: in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or,
- in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or,
- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.
As a result, we cannot recommend its use within NHSScotland.
Bempedoic acid / ezetimibe (Nustendi®) has previously been accepted for restricted use in adults with primary hypercholesterolaemia or mixed dyslipidaemia (SMC2406). This advice remains valid.
Download detailed advice240KB (PDF)
Medicine details
- Medicine name:
- bempedoic acid / ezetimibe (Nustendi)
- SMC ID:
- SMC2741
- Indication:
in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
• in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or,
• in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or,
• in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 June 2025